Episode Details
Back to Episodes
Week in Review | Bristol's CAR-T Pause Was Three Months Old Before the Public Heard
Published 1 week, 5 days ago
Description
Bristol Myers Squibb told regulators in early June. The rest of us found out this week, after an analyst note. Three months sat between those two facts, and that gap is the story of the week. Also this week, a cardiovascular outcomes trial in more than eight thousand patients missed its endpoint and put a whole drug class in question. A mid-stage lupus readout took fifty five percent off a company in a day. And the FDA approved a cancer drug over its own advisers, while memos surfaced on a second approval it had granted over its own reviewers. What do you do with a week like that?
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.